Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more. bySoujanya RaviMay 24, 2026